Ivonescimab's ASCO Plenary: What Akeso's Top Billing Reveals About Its Lung Cancer Data

As the American Society of Clinical Oncology (ASCO) annual meeting approaches, one of the most talked-about presentations is Akeso's ivonescimab, a bispecific antibody targeting PD-1 and VEGF. The company has earned a coveted plenary slot, sparking intense speculation about its survival data in non-small cell lung cancer (NSCLC). This Q&A breaks down what the buzz means, the substance behind the headlines, and what investors and clinicians should watch for.

What is ivonescimab and why is it drawing so much attention?

Ivonescimab (AK112) is a bispecific antibody developed by Akeso and licensed to Summit Therapeutics for ex-China rights. It simultaneously targets PD-1 and VEGF, two well‑validated pathways in cancer. This dual mechanism aims to overcome resistance to standard PD‑1 inhibitors by also blocking angiogenesis. The drug has already shown encouraging results in earlier‑line NSCLC, particularly in patients with high PD‑L1 expression. The excitement stems from the potential for improved efficacy over current checkpoint inhibitors, which could translate into a significant market opportunity. The upcoming ASCO plenary presentation will unveil detailed survival data from a Phase 3 trial, making it a potential landmark event for the field.

What does Akeso's plenary spot at ASCO signify?

ASCO plenary sessions are reserved for the most impactful clinical research of the year. Being selected for a plenary slot indicates that the data are considered practice‑changing or highly novel. For Akeso and Summit, this placement signals that the survival outcomes are statistically compelling and clinically meaningful. It also puts ivonescimab in the spotlight alongside other major advances, increasing visibility among oncologists, regulators, and investors. The plenary presentation typically includes a formal discussion by an expert, which further validates the findings. In the biotech world, such a spot often catalyzes stock price movements and partnership interest, as it suggests a high probability of regulatory approval and commercial success.

What survival data has been reported or is expected for ivonescimab?

While full results are embargoed until the ASCO presentation, previous disclosures provide clues. In a Phase 2 trial, ivonescimab showed a median progression‑free survival (PFS) of roughly 11 months in first‑line NSCLC with PD‑L1 ≥50%, compared to around 7‑8 months for pembrolizumab in similar patients. The Phase 3 trial, which is the subject of the plenary, randomizes ivonescimab against pembrolizumab in the same population. The key endpoint is overall survival (OS), with PFS as a secondary endpoint. Analysts expect that ivonescimab may demonstrate a statistically significant OS benefit, perhaps a hazard ratio below 0.75. If OS improvement is confirmed, it would position ivonescimab as a potential new standard of care for high PD‑L1 NSCLC.

How does ivonescimab compare to other lung cancer treatments in development?

Ivonescimab belongs to a growing class of bispecific antibodies, but it is the first to combine PD‑1 and VEGF inhibition in a single molecule. Competitors include other PD‑1/VEGF bispecifics (e.g., from BioNTech/Medigene) and combinations of PD‑1 inhibitors with anti‑VEGF agents like bevacizumab. However, a single‑agent bispecific could offer better tolerability and convenience. Compared to standard pembrolizumab, ivonescimab may have a different toxicity profile, with potentially fewer immune‑related adverse events due to VEGF blockade. If survival data are superior, it could challenge not only pembrolizumab but also combinations like chemotherapy plus immunotherapy. The plenary results will help clarify where ivonescimab fits in the treatment landscape.

What are the implications for Summit Therapeutics?

Summit Therapeutics licensed rights to ivonescimab in the U.S., Canada, Europe, and Japan in December 2022, paying $50 million upfront and agreeing to share development costs. The success of ivonescimab is critical for Summit, which has few other pipeline assets. Positive survival data could lead to a regulatory submission within 12‑18 months, potentially driving Summit's stock value significantly. Conversely, if the data disappoint, Summit would face a major setback, given its heavy reliance on this single drug. The ASCO plenary presentation will likely be a make‑or‑break moment for the company, influencing its ability to raise additional capital or secure partnerships.

What challenges does Akeso face in bringing ivonescimab to market?

Despite the promising data, Akeso faces several hurdles. First, manufacturing a bispecific antibody at scale is more complex than standard monoclonal antibodies, requiring robust quality control. Second, regulatory approval will depend on demonstrating a clear survival benefit over the current standard of care. Third, even with positive results, commercial uptake will require convincing oncologists to switch from well‑established drugs like pembrolizumab. Akeso also needs to address pricing and reimbursement, especially if the drug is used in first‑line settings. Additionally, the company must manage its relationship with Summit, ensuring smooth collaboration for global development. The ASCO plenary will provide clarity on the data, but execution in the clinic and marketplace will be equally important.

How important is an ASCO plenary for a biotech stock's performance?

An ASCO plenary presentation can dramatically impact a biotech's stock price. Historically, companies that present positive survival data in plenary sessions often see share price increases of 20‑50% or more in the days following the announcement. For example, when Merck presented Keynote‑024, its stock rose significantly. However, the effect is not guaranteed—if the data are already anticipated or if the magnitude of benefit is modest, the stock might actually decline. For Akeso and Summit, the plenary spot has already generated hype, so the actual results need to meet or exceed expectations. Investors should watch not only the hazard ratios but also the safety profile and the expert commentary after the presentation.

What should investors and clinicians watch for during the ASCO presentation?

Key details to focus on include the hazard ratio for overall survival and progression‑free survival, especially in the prespecified subgroups (e.g., PD‑L1 high vs. lower expression). Also important are the median survival times and the shape of the Kaplan‑Meier curves. Safety data—rates of grade 3‑4 adverse events, immune‑related toxicities, and treatment‑related deaths—will be critical for assessing the drug's risk‑benefit profile. Clinicians should note the patient demographics and whether the trial included Asian patients only or a global population, as that affects generalizability. Finally, listen for the discussant's comments, which often provide context on how the data might change practice. These elements will determine whether ivonescimab becomes a new standard or a niche player.